Middle East and Africa Protein A Resins Market Research Report – Segmented By Product Type, Application, End Users, Matrix Type & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 343
Pages: 135

MEA Protein A Resins Market Size (2024 to 2029)

As per our research, the Protein A Resins Market size in the Middle East & Africa was worth USD 53.77 million in 2024 and estimated to be growing at a CAGR of 8.79% to reach USD 81.94 million by 2029.

Protein A resin is based on affinity chromatography, and they are used as an easy one-step purification of immunoglobulins from biological fluids and cell culture media. In addition, these resins also find their use in immunoprecipitation of proteins, protein complexes or antigens, monoclonal antibodies, etc. Factors such as growing demand for biosimilars/biologics and increasing investment in research and biosimilars/proteomics are the significant drivers of the protein a resins market in this region. For instance, the protein A resin can cause inflammation in the lung tissue by binding to the tumor necrosis factor 1(TNFR-1) receptors. This interaction has been shown to detect the pathogenesis of pneumonia caused by staphylococci.

They can be used to study drugs, toxins, or radioactive substances directly to cancer cells and treat chronic diseases such as cancer and rheumatoid arthritis. The market shows clear potential during the forecast period owing to the increase in research and development supported by favorable government initiatives, which are estimated to drive the sales of Protein A. In addition, an increased prevalence of serious diseases such as cancer has led to investments in research and development to develop effective drugs, leading to an increase in the market demand for protein A resins. The rate of cancer is increasing by 1 to 1.30 % every year across the globe. In 2019, Pneumonia had caused over 14% of total deaths of children under the age of 5, accounting for 740,200 deaths. Although pneumonia affects children and families across the globe, however, the highest number of deaths have been recorded in South Asia and sub-Saharan Africa. In addition, the growing need for early diagnosis of the diseases, coupled with the increasing emphasis on good quality healthcare, will pave the way for growth opportunities during the forecast period.

The high cost of protein A resins coupled with growing awareness of alternative methods to purify monoclonal antibodies such as crystallization, ultrafiltration, capillary electrophoresis, and high-pressure folding are expected to slow down the growth rate of the MEA protein A resin market.

This research report on the Middle East and Africa Protein A Resins market has been segmented and sub-segmented into the following categories:

By Product Type: 

  • Natural Protein A Resin
  • Recombinant Protein A Resin

By Application: 

  • Immunoprecipitation
  • Antibody Purification

By Matrix Type: 

  • Glass or Silica
  • Agarose
  • Organic Polymer  

By End Users: 

  • Biopharmaceutical Manufacturers
  • Clinical Research Laboratories
  • Academic Institutions

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the Middle East is projected to dominate the MEA protein A resin market during the forecast period, owing to the increasing demand for the pharmaceuticals and biopharmaceuticals sector in the region.

Saudi Arabia is anticipated to register a 7.5% CAGR between 2024 to 2029 due to the increasing demand for therapeutic antibodies, and extensive research on monoclonal antibodies will drive the market. In addition, the growing prevalence of cancer has encouraged the government and pharmaceutical companies to invest in the studied market to increase the market revenue. This pharmaceutical market had sales and R&D over a value of approximately $ 235 million in 2018.

The Egypt protein A resin sales are expected to increase at an impressive 7.5% CAGR during the forecast period, owing to the region's high investment in biopharmaceutical companies. In 2018, Pharmaceuticals preparations, manufacturing, operating had seen a grand profit of approximately US $ 925 million.

The African region is expected to account for almost 15% of the share in MEA due to the growing number of biopharmaceutical companies focusing on the development of biosimilar drugs. In South Africa, the biopharmaceutical market reached approximately USD 3.6 billion in growing sales in 2018.


A few notable companies operating in the MEA Protein A Resins Market profiled in the report are GE Healthcare, Repligen Corporation, Novasep, Tosoh Bioscience, GenScript, Thermo Fisher Scientific EMD Millipore, and Expedeon Ltd.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample